The histamine autoreceptor is a short isoform of the H3 receptor (original) (raw)

Abstract

The histamine H3 receptor was identified as the autoreceptor of brain histaminergic neurons. After its cloning, functional H3 receptor isoforms generated by a deletion in the third intracellular loop were found in the brain. Here, we determined if this autoreceptor was the long or the short isoform. EXPERIMENTAL APPROACH We hypothesized that the deletion would affect H3 receptor stereoselectivity. The effects of the enantiomers of two chiral ligands, N a-methyl-a-chloromethylhistamine (N a Me-aClMeHA) and sopromidine, were investigated on cAMP formation at the H3(445) and H3(413) receptor isoforms, common to all species. They were further compared with their effects at autoreceptors. They were also compared on [ 35 S]GTPg[S] binding to membranes of rat cerebral cortex, striatum and hypothalamus, the richest area in autoreceptors. KEY RESULTS The stereoselectivity of N a Me-aClMeHA enantiomers as agonists was similar at the H3(413) receptor isoform and autoreceptors, but lower at the long isoform. While (S) sopromidine did not discriminate between the isoforms, (R) sopromidine was an antagonist at the H3(413) receptor isoform and autoreceptors, but a full agonist at the long isoform. In rat brain, stereoselectivity of N a Me-aClMeHA was higher in the hypothalamus than in cerebral cortex or striatum, whereas the opposite pattern was found for sopromidine. CONCLUSIONS AND IMPLICATIONS The pharmacological profiles of H3 receptor isoforms differed markedly, showing that the function of autoreceptors was fulfilled by a short isoform, such as the H3(413) receptor. Development of drugs selectively targeting autoreceptors might enhance their therapeutic efficacy and/or decrease incidence of side effects. Abbreviations aMeHA, a-methylhistamine; AA, arachidonic acid; IPX, iodoproxyfan; N a Me-aClMeHA, N a-methyl-achloromethylhistamine

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (65)

  1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
  2. Anichtchik OV, Huotari M, Peitsaro N, Haycock JW, Mannisto PT, Panula P (2000). Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12: 3823-3832.
  3. Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, Panula P (2001). Distribution and modulation of histamine H3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 8: 707-716.
  4. Arrang JM, Garbarg M, Schwartz JC (1983). Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302: 832-837.
  5. Arrang JM, Schwartz JC, Schunack W (1985a). Stereoselectivity of the histamine H3-presynaptic autoreceptor. Eur J Pharmacol 117: 109-114.
  6. Arrang JM, Garbarg M, Quach TT, Dam Trung Tuong M, Yeramian E, Schwartz JC (1985b). Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 111: 73-84.
  7. Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M et al. (1987). Highly potent and selective ligands for histamine H3-receptors. Nature 327: 117-123.
  8. Arrang JM, Roy J, Morgat JL, Schunack W, Schwartz JC (1990). Histamine H3 receptor binding sites in rat brain membranes: modulations by guanine nucleotides and divalent cations. Eur J Pharmacol 188: 219-227.
  9. Arrang JM, Morisset S, Gbahou F (2007). Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 28: 350-357.
  10. Bongers G, Krueger KM, Miller TR, Baranowski JL, Estvander BR, Witte DG et al. (2007). An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. J Pharmacol Exp Ther 323: 888-898.
  11. Burban A, Sadakhom C, Dumoulin D, Rose C, Le Pen G, Frances H et al. (2010). Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl) 210: 591-604.
  12. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ (2005). Histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 10: 1613-1627.
  13. Centonze D, Usiello A, Gubellini P, Pisani A, Borrelli E, Bernardi G et al. (2002). Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2 L receptors. Neuropsychopharmacology 27: 723-726.
  14. Cheng Y, Prussoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
  15. Coge F, Guenin SP, Audinot V, Renouard-Try A, Beauverger P, Macia C et al. (2001). Genomic organization and characterization of splice variants of the human histamine H3 receptor. Biochem J 355: 279-288.
  16. Cumming P, Shaw C, Vincent SR (1991). High affinity histamine binding site is the H3 receptor: characterization and autoradiographic localization in rat brain. Synapse 8: 144-151.
  17. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H et al. (2001). Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59: 1-8.
  18. Esbenshade TA, Fox GB, Cowart MD (2006). Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6: 77-88, 59.
  19. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS et al. (2003). Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci U S A 100: 11086-11091.
  20. Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C, Arrang JM (2006). Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 147: 744-754.
  21. Gbahou F, Davenas E, Morisset S, Arrang JM (2010). Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther 334: 945-954.
  22. Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P et al. (1999). Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur J Neurosci 11: 449-456.
  23. Guiramand J, Montmayeur JP, Ceraline J, Bhatia M, Borrelli E (1995). Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 270: 7354-7358.
  24. Haas HL, Sergeeva OA, Selbach O (2008). Histamine in the nervous system. Physiol Rev 88: 1183-1241.
  25. Hancock AA (2003). H3 receptor antagonists/inverse agonists as anti-obesity agents. Curr Opin Investig Drugs 4: 1190-1197.
  26. Hancock AA, Fox GB (2004). Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13: 1237-1248.
  27. Hancock AA, Esbenshade TA, Krueger KM, Yao BB (2003). Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 73: 3043-3072.
  28. Jomphe C, Tiberi M, Trudeau LE (2006). Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology 50: 595-605.
  29. Kamei C (2001). Involvement of central histamine in amygdaloid kindled seizures in rats. Behav Brain Res 124: 243-250.
  30. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS (1998). Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 95: 7731-7736.
  31. Krause M, Stark H, Schunack W (1997). Iododestannylation: an improved synthesis of [ 125 I]iodoproxyfan, a specific radioligand of the histamine H3 receptor. J Labelled Comp Radiopharm 39: 601-606.
  32. Leurs R, Bakker RA, Timmerman H, de Esch IJ (2005). The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4: 107-120.
  33. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R et al. (2008). An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 30: 74-83.
  34. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P et al. (2003). Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A 100: 4305-4309.
  35. Liu LX, Monsma FJ Jr, Sibley DR, Chiodo LA (1996). D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse 24: 156-164.
  36. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A et al. (1999). Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55: 1101-1107.
  37. Mezzomo K, Cumming P, Minuzzi L (2007). Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography. Eur J Pharmacol 564: 75-79.
  38. Moreno-Delgado D, Gomez-Ramirez J, Torrent-Moreno A, Gonzalez-Sepulveda M, Blanco I, Ortiz J (2009). Different role of cAMP dependent protein kinase and CaMKII in H3 receptor regulation of histamine synthesis and release. Neuroscience 164: 1244-1251.
  39. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H et al. (2000). High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408: 860-864.
  40. Morisset S, Sasse A, Gbahou F, Héron A, Ligneau X, Tardivel-Lacombe J et al. (2001). The rat H3 receptor: gene organization and multiple isoforms. Biochem Biophys Res Commun 280: 75-80.
  41. Motawaj M, Arrang JM (2011). Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 33: 1197-1204.
  42. Panula P, Airaksinen M (1991). The histaminergic neuronal system as revealed with antisera against histamine. In: Watanabe T, Wada H (eds). Histaminergic Neurons: Morphology and Function. CRC: Boca Raton, FL, pp. 127-144.
  43. Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T et al. (2007). The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 73: 1157-1171.
  44. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004). The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25: 618-625.
  45. Pillot C, Héron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC et al. (2002). A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience 114: 173-193.
  46. Pollard H, Moreau J, Arrang JM, Schwartz JC (1993). A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52: 169-189.
  47. Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC et al. (2002). Histamine H3-receptor-mediated [ 35 S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br J Pharmacol 135: 383-392.
  48. Rouleau A, Héron A, Cochois V, Pillot C, Schwartz JC, Arrang JM (2004). Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. J Neurochem 90: 1331-1338.
  49. Schlicker E, Malinowska B, Kathmann M, Gothert M (1994). Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 8: 128-137.
  50. Senogles SE (1994). The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J Biol Chem 269: 23120-23127.
  51. Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA et al. (2009). Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology (Berl) 201: 483-494.
  52. Stevens DR, Eriksson KS, Brown RE, Haas HL (2001). The mechanism of spontaneous firing in histamine neurons. Behav Brain Res 124: 105-112.
  53. Strakhova MI, Fox GB, Carr TL, Witte DG, Vortherms TA, Manelli AM et al. (2008). Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur J Pharmacol 601: 8-15.
  54. Takeshita Y, Watanabe T, Sakata T, Munakata M, Ishibashi H, Akaike N (1998). Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. Neuroscience 87: 797-805.
  55. Tardivel-Lacombe J, Rouleau A, Héron A, Morisset S, Pillot C, Cochois V et al. (2000). Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms. Neuroreport 11: 755-759.
  56. Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC, Arrang JM (2001). Chromosomal mapping and organization of the human histamine H3 receptor gene. Neuroreport 12: 321-324.
  57. Tohyama M, Tamiya R, Inagaki N, Takagi H (1991). Morphology of histaminergic neurons with histidine decarboxylase as a marker. In: Watanabe T, Wada H (eds). Histaminergic Neurons: Morphology and Function. CRC: Boca Raton, FL, pp. 107-126.
  58. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al. (2000). Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408: 199-203.
  59. Van H II, Banihashemi B, Wilson AM, Jacobsen KX, Czesak M, Albert PR (2007). Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation. J Neurochem 102: 1796-1804.
  60. Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM (2002). Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology 42: 929-940.
  61. Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R et al. (2006). Detection of multiple H3 receptor affinity states utilizing [ 3 H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand. Br J Pharmacol 148: 657-670.
  62. Wolfe SE, Morris SJ (1999). Dopamine D2 receptor isoforms expressed in AtT20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J Neurochem 73: 2375-2382.
  63. Wouterlood F, Steinbusch H (1991). Afferent and efferent fiber connections of histaminergic neurons in the rat brain: comparison with dopaminergic, noradrenergic and serotonergic systems. In: Watanabe T, Wada H (eds). Histaminergic Neurons: Morphology and Function. CRC: Boca Raton, FL, pp. 145-162.
  64. Wulff BS, Hastrup S, Rimvall K (2002). Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol 453: 33-41.
  65. Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S et al. (2006). Use of an inverse agonist radioligand [ 3 H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor. Neuropharmacology 50: 468-478.